Format

Send to

Choose Destination
Trends Mol Med. 2016 Jan;22(1):10-27. doi: 10.1016/j.molmed.2015.11.004. Epub 2015 Dec 12.

HIV-1 Eradication: Early Trials (and Tribulations).

Author information

1
Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
2
Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA. Electronic address: vicente.planelles@path.utah.edu.

Abstract

Antiretroviral therapy (ART) has rendered HIV-1 infection a manageable illness for those with access to treatment. However, ART does not lead to viral eradication owing to the persistence of replication-competent, unexpressed proviruses in long-lived cellular reservoirs. The potential for long-term drug toxicities and the lack of access to ART for most people living with HIV-1 infection have fueled scientific interest in understanding the nature of this latent reservoir. Exploration of HIV-1 persistence at the cellular and molecular level in resting memory CD4(+) T cells, the predominant viral reservoir in patients on ART, has uncovered potential strategies to reverse latency. We review recent advances in pharmacologically based 'shock and kill' HIV-1 eradication strategies, including comparative analysis of early clinical trials.

PMID:
26691297
PMCID:
PMC5889129
DOI:
10.1016/j.molmed.2015.11.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center